Asciminib, ponatinib, nilotinib and bosutinib can raise two pancreas enzymes in the blood, lipase and amylase, and can sometimes inflame the pancreas (pancreatitis). Blood tests look for this: monthly on asciminib and nilotinib, and every 2 weeks for the first 2 months on ponatinib. Tell your team right away about sudden or severe stomach pain, feeling sick or being sick.
Scope: adults taking asciminib, ponatinib, nilotinib or bosutinib. The rules are the labels' own; a unit's protocol and the treating haematologist's judgement come first.
Asciminib (US label and EU SmPC agree): assess lipase and amylase monthly, or as clinically indicated, and more often after past pancreatitis. Asymptomatic amylase or lipase above 2 x ULN: withhold until below 1.5 x ULN, then resume at a reduced dose; permanently discontinue if it recurs at the reduced dose; if it does not resolve, permanently discontinue and perform diagnostic tests to exclude pancreatitis. With abdominal symptoms: temporarily withhold and consider tests to exclude pancreatitis. In the US label's 556 patients, enzymes rose in 20% (grade 3 in 7%, grade 4 in 2%) and pancreatitis occurred in 2%.
Ponatinib: lipase every 2 weeks for the first 2 months, then monthly (US) or periodically (EU). The two labels differ. US: lipase above 1 to 1.5 x ULN, consider interrupting; above 1.5 to 2 x ULN, or 2 to 5 x ULN without symptoms, or asymptomatic radiologic pancreatitis, interrupt until below 1.5 x ULN and resume at the next lower dose; lipase 2 to 5 x ULN with symptoms, symptomatic grade 3 pancreatitis, or above 5 x ULN without symptoms, interrupt until symptoms resolve and lipase is grade 0 or 1, then resume at the next lower dose; symptomatic pancreatitis with lipase above 5 x ULN, discontinue. EU: at grade 2, continue at the same dose; for asymptomatic lipase above 5 x ULN or grade 3 pancreatitis, withhold and resume one dose level lower (45 to 30 to 15 mg), and at 15 mg discontinuation should be considered; grade 4, discontinue. The US label's warning says pancreatitis occurred in 26% to 34% of patients across three trials, serious or severe (grade 3 or 4) in 15% to 17%; its adverse reaction tables print the same figures for two of the trials under "Pancreatitis/lipase elevation", a term it does not define, so the count is not clinical pancreatitis alone.
Nilotinib: lipase monthly or as clinically indicated. US: for lipase or amylase of grade 3 or above in adults, withhold and resume at 400 mg once daily when grade 1 or less. EU: for grade 3 to 4 lipase, reduce to 400 mg once daily or interrupt. Bosutinib: the EU SmPC asks for interruption, and tests to be considered, when raised lipase comes with abdominal symptoms; the US label has no pancreatitis warning and no lipase schedule.
The ELN's 2016 consensus (not graded) recommends withholding for asymptomatic grade 3 enzymes, a CT scan where there are symptoms, stopping nilotinib for grade 3 pancreatitis or a positive scan, and stopping any TKI for grade 4. The ELN's 2025 recommendations call nilotinib inadvisable after past pancreatitis; the 2020 edition also preferred TKIs other than bosutinib. CTCAE version 5.0 puts grade 3 lipase at above 2 to 5 x ULN with signs or symptoms, or above 5 x ULN without; version 6.0 moves that lower boundary from 2 to 3 x ULN.
Why: Both asciminib labels ask for more frequent monitoring after past pancreatitis. No label read tells the prescriber to ask about it in so many words; the US patient leaflets for asciminib, ponatinib and nilotinib ask patients to tell their healthcare provider, before taking the medicine, if they have had pancreatitis. The US ponatinib label says to consider additional lipase monitoring where there is a history of pancreatitis or alcohol abuse, and the EU SmPC recommends caution in the same people. The US nilotinib label says people who have had pancreatitis may be at greater risk of raised lipase, and the EU SmPCs of nilotinib and bosutinib recommend caution. No label read says how much more often to test, and none lists past pancreatitis as a contraindication.
“Perform more frequent monitoring in patients with a history of pancreatitis.”
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026
Why: The sentence comes from the 2025 paper's section on choosing a first medicine, and it gives no reason there. The 2020 edition, which the 2025 paper revises, gave one: raised lipase, sometimes with pancreatitis, has been reported after nilotinib and bosutinib, so in people with a history of pancreatitis other TKIs are preferred. It also called that history a contraindication to nilotinib. The 2025 paper does not repeat the sentence on bosutinib and pancreatitis. The labels are less strict: they ask for caution or closer monitoring.
“Nilotinib is inadvisable in patients with diabetes mellitus, high or very high cardiovascular risk including a history of vaso-occlusive events (VOEs) or pancreatitis.”
Why: The EU SmPC says the same. In the 556 patients behind the US label, lipase and amylase rose in 20% and pancreatitis occurred in 2%. The labels also ask for patients to be monitored for signs and symptoms of pancreatic toxicity.
“Assess serum lipase and amylase levels monthly during treatment with SCEMBLIX, or as clinically indicated.”
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026
Why: The EU SmPC says the frequency of pancreatitis is greater in the first 2 months of use. In the US label the median time to onset was 8 days in PhALLCON, 1 month in OPTIC and 29 days in PACE. Neither label asks for amylase.
“Monitor serum lipase every 2 weeks for the first 2 months and then monthly thereafter or as clinically indicated.”
Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026
Why: The US label says nilotinib can cause increases in serum lipase; the EU SmPC gives the same monthly test. Neither bosutinib label sets a schedule for lipase: the EU SmPC says only that elevation in serum lipase has been observed.
“Test serum lipase levels monthly or as clinically indicated.”
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2025
Why: The quote is the US asciminib label; the EU SmPC matches it. The nilotinib labels (US and EU) and the EU bosutinib SmPC say to interrupt and to consider diagnostic measures to exclude pancreatitis. The US ponatinib label says to evaluate for pancreatitis, and the EU SmPC that ponatinib should be withheld and the patient evaluated for evidence of pancreatitis. The labels give no reason beyond excluding pancreatitis.
“If lipase and amylase elevation are accompanied by abdominal symptoms, temporarily withhold SCEMBLIX and consider appropriate diagnostic tests to exclude pancreatitis”
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026
Why: The ELN panel notes that lipase or amylase may rise without evidence of pancreatitis, with all TKIs, and asks for high awareness on nilotinib and ponatinib. It also says that with abdominal pain, gastric and pancreatic problems must be ruled out. This is a consensus of experts, not graded.
“Suspicion of pancreatitis is always a call for action, and the advice of an appropriate gastroenterologist or surgeon may be needed.”
Why: NICE lists prescription drugs as one of several other possible causes to investigate. This is general guidance for anyone with acute pancreatitis, it was not written for people on cancer treatment, and it names no medicine. NICE also says not to assume that pancreatitis is alcohol-related just because the person drinks alcohol.
“If gallstones and alcohol have been excluded as potential causes of a person's acute pancreatitis, investigate other possible causes such as: metabolic causes (such as hypercalcaemia or hyperlipidaemia) prescription drugs”
Why: The US label and the EU SmPC give the same rule. The reduced dose is 40 mg once daily or 20 mg twice daily, or 160 mg twice daily for people on the 200 mg twice daily dose used for the T315I mutation. Where the rise does not resolve, both labels say to permanently discontinue and to perform diagnostic tests to exclude pancreatitis. Neither gives a reason.
“Withhold SCEMBLIX until resolved to less than 1.5 x ULN. If resolved: Resume SCEMBLIX at reduced dose. If events reoccur at reduced dose, permanently discontinue SCEMBLIX.”
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026
Why: The two labels differ here. The US label also includes pancreatitis seen on a scan without symptoms in this row, and for a smaller rise (above 1 to 1.5 x ULN) says to consider interrupting until resolution and then to resume at the same dose. The EU SmPC's table starts at grade 2, where it says to continue at the same dose. Neither label gives a reason for its choice.
“Interrupt ICLUSIG until Grade 0 or 1 (less than 1.5 times ULN), then resume at next lower dose.”
Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026
Why: The EU SmPC splits this into two rows. For asymptomatic lipase above 5 x ULN it says to withhold and resume one dose level lower (30 mg after 45 mg, 15 mg after 30 mg) after recovery to grade 1 or less, below 1.5 x ULN. For grade 3 pancreatitis or a symptomatic grade 3 rise it says to withhold until symptoms have completely resolved and lipase is below grade 2. In both rows it says that at 15 mg discontinuation should be considered. The US label's dose reductions for chronic-phase CML are 30 mg, then 15 mg, then 10 mg once daily, and it says to permanently discontinue in people unable to tolerate 10 mg.
“Interrupt ICLUSIG until complete resolution of symptoms and after recovery of lipase elevation Grade 0 or 1, then resume at next lower dose.”
Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026
Why: The EU SmPC says the same in its own terms: discontinue for grade 4 pancreatitis or a grade 4 rise in lipase, which it defines as above 5 x the institution's upper limit of normal with symptoms. Neither label uses the word permanently here, and neither gives a reason.
“Symptomatic pancreatitis and serum lipase greater than 5 times ULN Discontinue ICLUSIG.”
Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026
Why: The EU SmPC differs: for grade 3 to 4 lipase it says the adult dose should be reduced to 400 mg once daily or interrupted, and it does not name amylase. Neither label states the multiples of the upper limit of normal it means by grade 3, and neither gives a reason.
“1. Withhold Tasigna, and monitor serum lipase or amylase. 2. Resume treatment at 400 mg once daily if serum lipase or amylase returns to less than or equal to Grade 1.”
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2025
Why: The EU SmPC also recommends caution in people who have had pancreatitis. The US label has no warning on pancreatitis or lipase; it lists pancreatitis among adverse reactions in 1% to less than 10% of patients, under a term that also counts raised pancreatic enzymes. Its general rule for other clinically significant, moderate or severe non-haematological toxicity is to withhold until the toxicity has resolved and then to consider resuming at a dose reduced by 100 mg once daily; the EU SmPC has a matching general rule.
“In case lipase elevations are accompanied by abdominal symptoms, bosutinib should be interrupted and appropriate diagnostic measures considered to exclude pancreatitis”
Pfizer Europe (manufacturer's document, published by the European Medicines Agency) 2025
Why: This is the expert panel's recommended approach; the paper does not mention asciminib. It differs from the labels: the asciminib labels act at above 2 x ULN and the US ponatinib label at above 1.5 x ULN. For symptoms the panel says that if the CT scan is positive or the pancreatitis is grade 3, stopping nilotinib is mandatory, while for ponatinib withholding and resuming at a lower dose could be reasonable; for grade 4 pancreatitis it says stopping is mandatory whichever TKI is being taken.
“If the patient is asymptomatic but with grade 3 lipase/amylase elevation, withholding therapy and resuming at a lower dose when the grade is <2 is the recommended approach.”
Why: The EU SmPC says this is to reduce the risk of pancreatitis. It does not say how, or give a triglyceride figure. The US label has no matching sentence.
“Patients with severe or very severe hypertriglyceridemia should be appropriately managed to reduce the risk of pancreatitis.”
Why: The US patient leaflets for asciminib, ponatinib and nilotinib say to tell the healthcare provider right away. The US nilotinib label asks prescribers to advise patients to seek immediate medical attention for sudden stomach area pain with nausea and vomiting. The EU ponatinib leaflet says to stop taking it and contact a doctor or go to the nearest emergency department immediately for severe pain in the stomach and back.
“Inform patients of the possibility of developing pancreatitis that may be accompanied by nausea, vomiting, severe abdominal pain, or abdominal discomfort, and to promptly report these symptoms”
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026
How care is usually carried out, read from the guidelines and standards cited. Your own team's protocol and their judgement come first; this page is for understanding it, not for doing it yourself.
No graded guideline covers this problem; the labels are the source for each medicine's rule, and they differ from one another and, for ponatinib, nilotinib and bosutinib, between the United States and the European Union. What the asciminib, ponatinib and nilotinib labels share is lipase tested on a schedule (monthly on asciminib, with amylase, and on nilotinib; every 2 weeks for the first 2 months on ponatinib); neither bosutinib label sets one. When a raised result comes with abdominal symptoms, the asciminib and nilotinib labels, the EU ponatinib SmPC and the EU bosutinib SmPC say to withhold or interrupt the medicine while pancreatitis is looked for; the US ponatinib label says to evaluate for pancreatitis and the US bosutinib label says nothing. Where they differ is the result that triggers a hold without symptoms: above 2 x ULN on asciminib (US and EU), above 1.5 x ULN on ponatinib in the US label against above 5 x ULN in the EU SmPC, and grade 3 on nilotinib. The ELN's 2016 expert consensus, which is not graded and does not mention asciminib, withholds at asymptomatic grade 3 and asks for a CT scan where there are symptoms. The US labels, the EU SmPCs and the ELN's advice are all on this page; none is ranked above the others.
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026 · Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2026 · Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026 · Incyte Biosciences Distribution (manufacturer's document, published by the European Medicines Agency) 2026 · Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2025 · Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2025 · Pfizer Laboratories (manufacturer's label, approved by the FDA) 2026 · Pfizer Europe (manufacturer's document, published by the European Medicines Agency) 2025 · Leukemia (Steegmann et al., European LeukemiaNet; authors declare honoraria and research funding from Ariad, Bristol-Myers Squibb, Novartis and Pfizer) 2016
Where it differs: Monitoring after the first 2 months is monthly in the US label and 'periodically' in the EU SmPC. At grade 2 (lipase above 1.5 to 2 x ULN, or above 2 to 5 x ULN without symptoms) the US label interrupts and resumes at the next lower dose, and the EU SmPC continues at the same dose. For lipase above 1 to 1.5 x ULN the US label says to consider interrupting; the EU table has no row for it. For lipase above 5 x ULN without symptoms both withhold and step the dose down, and the EU SmPC adds that at 15 mg discontinuation should be considered. For symptomatic pancreatitis with lipase above 5 x ULN both discontinue. Only the EU SmPC asks for severe or very severe hypertriglyceridaemia to be managed, and only the EU SmPC carries paediatric tables.
Evidence: Regulatory labels; not graded. US label: pancreatitis in 34% of 163 patients in PhALLCON, 29% of 94 in OPTIC and 26% of 449 in PACE, serious or severe (grade 3 or 4) in 15%, 16% and 17%. Its adverse reaction tables print the PhALLCON and OPTIC figures under "Pancreatitis/lipase elevation", which it does not define, and it counts clinical pancreatitis that led to a dose change separately (7 patients in PhALLCON, 2 in OPTIC and 28 cases in PACE). The US table is based on CTCAE version 5.0.
Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026 · Incyte Biosciences Distribution (manufacturer's document, published by the European Medicines Agency) 2026
Where it differs: For grade 3 or higher, the US label names lipase or amylase and withholds, resuming at 400 mg once daily at grade 1 or less. The EU SmPC names lipase only and says the dose should be reduced to 400 mg once daily or interrupted. Both test lipase monthly or as clinically indicated, and both interrupt and consider diagnostics when a rise comes with abdominal symptoms.
Evidence: Regulatory labels; not graded. Neither dose rule states which CTCAE version, or which multiple of the upper limit of normal, defines its grade 3.
Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2025 · Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2025
Where it differs: The EU SmPC has a 'Serum lipase' warning: caution after past pancreatitis, and interruption with diagnostic measures considered when a rise comes with abdominal symptoms. The US label has no pancreatitis or lipase warning and no lipase schedule; it lists pancreatitis as an adverse reaction and reports lipase increased among laboratory abnormalities (36% of adults). Both have a general rule for clinically significant moderate or severe non-haematological toxicity.
Evidence: Regulatory labels; not graded.
Pfizer Laboratories (manufacturer's label, approved by the FDA) 2026 · Pfizer Europe (manufacturer's document, published by the European Medicines Agency) 2025
Where it differs: The ELN withholds at an asymptomatic grade 3 rise in lipase or amylase, resumes at a lower dose when the grade is below 2 and stops if full recovery takes more than 4 weeks. The asciminib labels act earlier (above 2 x ULN) and the US ponatinib label earlier still (above 1.5 x ULN); no label sets a 4-week limit. For symptoms the ELN recommends a CT scan, which no label names; the labels say diagnostic tests or evaluation. The ELN makes stopping nilotinib mandatory for grade 3 pancreatitis or a positive CT scan; the nilotinib labels say to interrupt and consider diagnostics and give no stop rule for pancreatitis itself.
Evidence: Expert consensus by email and meetings in 2014 and 2015; not graded. Its authors declare honoraria and research funding from Ariad, Bristol-Myers Squibb, Novartis and Pfizer. It reports lipase rises in 29 to 47% of people on nilotinib (grade 3 to 4 in 6 to 18%) with pancreatitis in 0.9% to 2%.
Leukemia (Steegmann et al., European LeukemiaNet; authors declare honoraria and research funding from Ariad, Bristol-Myers Squibb, Novartis and Pfizer) 2016 · Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026 · Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026 · Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2025
Where it differs: The 2025 ELN recommendations, the current edition, call nilotinib inadvisable in people with a history of pancreatitis. The 2020 edition preferred TKIs other than nilotinib and bosutinib in them and called that history a contraindication to nilotinib; the 2025 paper does not repeat the sentence on bosutinib. The labels do not contraindicate any of the four medicines: asciminib asks for more frequent monitoring, the US ponatinib label says to consider additional lipase monitoring, and the EU SmPCs of ponatinib, nilotinib and bosutinib recommend caution.
Evidence: Expert consensus (ELN; not graded) against regulatory labels (not graded). ELN 2020 says pancreatitis has been reported in about 5% of people treated with nilotinib.
Leukemia (Hochhaus et al., European LeukemiaNet; panel members declare research support and honoraria from manufacturers including Novartis, Pfizer, Incyte and Takeda) 2020 · Leukemia (Apperley et al., European LeukemiaNet; the paper states that no funding was received from any commercial source) 2025 · Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026 · Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026 · Incyte Biosciences Distribution (manufacturer's document, published by the European Medicines Agency) 2026 · Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2025 · Pfizer Europe (manufacturer's document, published by the European Medicines Agency) 2025
Where it differs: Version 5.0: grade 1 is above ULN to 1.5 x ULN; grade 2 is above 1.5 to 2.0 x ULN, or above 2.0 to 5.0 x ULN and asymptomatic; grade 3 is above 2.0 to 5.0 x ULN with signs or symptoms, or above 5.0 x ULN and asymptomatic; grade 4 is above 5.0 x ULN with signs or symptoms. Version 6.0 moves the boundary inside grades 2 and 3 for lipase from 2.0 to 3.0 x ULN. For amylase, version 6.0 keeps 2.0 x ULN and places mild signs or symptoms in grade 2. Both versions define pancreatitis grade 3 as severe pain, vomiting, or medical intervention indicated.
Evidence: NCI terminology, not a treatment guideline. The US ponatinib table says it is based on version 5.0. The asciminib dose tables cite version 4.03, which was not read, for their grade 3 non-haematological row only; their amylase and lipase row is written in multiples of ULN and does not depend on the version. The ponatinib lipase rows give multiples of ULN beside each grade.
US National Cancer Institute 2017 · US National Cancer Institute 2025 · Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026 · Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026 · Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2026
| Recommendation | Grade, as printed | Source |
|---|---|---|
| Asciminib: lipase and amylase monthly (EU wording) “Serum lipase and amylase levels should be assessed monthly during treatment with asciminib, or as clinically indicated.” | Regulatory label; not graded | Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2026 |
| Asciminib: asymptomatic amylase or lipase above 2 x ULN, withhold until below 1.5 x ULN (EU wording) “Withhold asciminib until resolved to <1.5 x ULN.” | Regulatory label; not graded | Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2026 |
| Asciminib: where the rise does not resolve, permanently discontinue and test for pancreatitis (US wording) “Permanently discontinue SCEMBLIX. Perform diagnostic tests to exclude pancreatitis.” | Regulatory label; not graded | Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2026 |
| Ponatinib: lipase above 1 to 1.5 x ULN (US label only) “Consider interrupting ICLUSIG until resolution, then resume at same dose.” | Regulatory label; not graded | Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026 |
| Ponatinib: lipase every 2 weeks for 2 months, then periodically (EU wording) “Check serum lipase every 2 weeks for the first 2 months and then periodically thereafter.” | Regulatory label; not graded | Incyte Biosciences Distribution (manufacturer's document, published by the European Medicines Agency) 2026 |
| Ponatinib: raised lipase with abdominal symptoms (EU wording) “If lipase elevations are accompanied by abdominal symptoms, Iclusig should be withheld and patients evaluated for evidence of pancreatitis” | Regulatory label; not graded | Incyte Biosciences Distribution (manufacturer's document, published by the European Medicines Agency) 2026 |
| Ponatinib: additional monitoring after past pancreatitis or alcohol abuse (US wording) “Consider additional serum lipase monitoring in patients with a history of pancreatitis or alcohol abuse.” | Regulatory label; not graded | Takeda Pharmaceuticals America (manufacturer's label, approved by the FDA) 2026 |
| Nilotinib: grade 3 to 4 lipase in adults (EU wording) “For Grade 3-4 serum lipase elevations, doses in adult patients should be reduced to 400 mg once daily or interrupted.” | Regulatory label; not graded | Novartis Europharm (manufacturer's document, published by the European Medicines Agency) 2025 |
| Nilotinib: raised lipase with abdominal symptoms (US wording) “If lipase elevations are accompanied by abdominal symptoms, interrupt dosing and consider appropriate diagnostics to exclude pancreatitis” | Regulatory label; not graded | Novartis Pharmaceuticals Corporation (manufacturer's label, approved by the FDA) 2025 |
| Bosutinib: general rule for other non-haematological toxicity (US wording) “For other clinically significant, moderate or severe non-hematological toxicity, withhold BOSULIF until the toxicity has resolved, then consider resuming BOSULIF at a dose reduced by 100 mg taken once daily.” | Regulatory label; not graded | Pfizer Laboratories (manufacturer's label, approved by the FDA) 2026 |
| Stop if full recovery of an asymptomatic grade 3 rise takes more than 4 weeks “If full recovery takes more than 4 weeks, therapy should be stopped.” | Expert consensus; not graded | Leukemia (Steegmann et al., European LeukemiaNet; authors declare honoraria and research funding from Ariad, Bristol-Myers Squibb, Novartis and Pfizer) 2016 |
| Stopping is mandatory for grade 4 pancreatitis, whichever TKI “Stopping therapy is mandatory for pancreatitis grade 4, irrespective of whether the concurrent TKI is thought to be causal.” | Expert consensus; not graded | Leukemia (Steegmann et al., European LeukemiaNet; authors declare honoraria and research funding from Ariad, Bristol-Myers Squibb, Novartis and Pfizer) 2016 |
| A history of pancreatitis as a contraindication to nilotinib “because pancreatitis has been reported in about 5% of treated patients, a history of pancreatitis also represents a contraindication to nilotinib use.” | Expert consensus; not graded | Leukemia (Hochhaus et al., European LeukemiaNet; panel members declare research support and honoraria from manufacturers including Novartis, Pfizer, Incyte and Takeda) 2020 |
| Nilotinib inadvisable after pancreatitis “Nilotinib is inadvisable in patients with diabetes mellitus, high or very high cardiovascular risk including a history of vaso-occlusive events (VOEs) or pancreatitis.” | Expert consensus; not graded | Leukemia (Apperley et al., European LeukemiaNet; the paper states that no funding was received from any commercial source) 2025 |
Shares Raised cholesterol and triglycerides, and weight gain, on lorlatinib, bexarotene and elacestrant, CTCAE toxicity grading (grade 3-4 adverse events), Dose reduction, interruption and discontinuation.